These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 34378456

  • 1. CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis.
    Comi G, Dadon Y, Sasson N, Steinerman JR, Knappertz V, Vollmer TL, Boyko A, Vermersch P, Ziemssen T, Montalban X, Lublin FD, Rocca MA, Volkinshtein R, Rubinchick S, Halevy N, Filippi M.
    Mult Scler; 2022 Apr; 28(4):608-619. PubMed ID: 34378456
    [Abstract] [Full Text] [Related]

  • 2. Placebo-controlled trial of oral laquinimod for multiple sclerosis.
    Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, Filippi M, ALLEGRO Study Group.
    N Engl J Med; 2012 Mar 15; 366(11):1000-9. PubMed ID: 22417253
    [Abstract] [Full Text] [Related]

  • 3. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.
    Filippi M, Rocca MA, Pagani E, De Stefano N, Jeffery D, Kappos L, Montalban X, Boyko AN, Comi G, ALLEGRO Study Group.
    J Neurol Neurosurg Psychiatry; 2014 Aug 15; 85(8):851-8. PubMed ID: 24029546
    [Abstract] [Full Text] [Related]

  • 4. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
    Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdova E, Komoly S, Selmaj K, Sharrack B, Filippi M, LAQ/5062 Study Group.
    Lancet; 2008 Jun 21; 371(9630):2085-92. PubMed ID: 18572078
    [Abstract] [Full Text] [Related]

  • 5. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis.
    Vollmer TL, Sorensen PS, Selmaj K, Zipp F, Havrdova E, Cohen JA, Sasson N, Gilgun-Sherki Y, Arnold DL, BRAVO Study Group.
    J Neurol; 2014 Apr 21; 261(4):773-83. PubMed ID: 24535134
    [Abstract] [Full Text] [Related]

  • 6. A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis.
    Giovannoni G, Knappertz V, Steinerman JR, Tansy AP, Li T, Krieger S, Uccelli A, Uitdehaag BMJ, Montalban X, Hartung HP, Pia Sormani M, Cree BAC, Lublin F, Barkhof F.
    Neurology; 2020 Aug 25; 95(8):e1027-e1040. PubMed ID: 32651286
    [Abstract] [Full Text] [Related]

  • 7. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ, Figgitt DP.
    CNS Drugs; 2004 Aug 25; 18(6):379-96. PubMed ID: 15089110
    [Abstract] [Full Text] [Related]

  • 8. Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study.
    Comi G, Abramsky O, Arbizu T, Boyko A, Gold R, Havrdová E, Komoly S, Selmaj K, Sharrack B, Filippi M, LAQ/5063 Study Group.
    Mult Scler; 2010 Nov 25; 16(11):1360-6. PubMed ID: 20834039
    [Abstract] [Full Text] [Related]

  • 9. Laquinimod for multiple sclerosis.
    He D, Han K, Gao X, Dong S, Chu L, Feng Z, Wu S.
    Cochrane Database Syst Rev; 2013 Aug 06; (8):CD010475. PubMed ID: 23922214
    [Abstract] [Full Text] [Related]

  • 10. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
    Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T, Laquinimod in Relapsing MS Study Group.
    Neurology; 2005 Mar 22; 64(6):987-91. PubMed ID: 15781813
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD.
    Lancet Neurol; 2014 Jun 22; 13(6):545-56. PubMed ID: 24685276
    [Abstract] [Full Text] [Related]

  • 12. Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS.
    Ziemssen T, Tumani H, Sehr T, Thomas K, Paul F, Richter N, Samara E, Spiegelstein O, Sorani E, Bar-Ilan O, Mimrod D, Hayardeny L.
    J Neuroinflammation; 2017 Aug 31; 14(1):172. PubMed ID: 28859672
    [Abstract] [Full Text] [Related]

  • 13. [Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial].
    Boyko AN, Boyko OV, Bakhtiyarova KZ, Gusev EI, Dudin VA, Zaslavsky LG, Malkova NA, Parshina YV, Poverennova IY, Siverceva SA, Totolyan NA, Shchur SG, Fedulov AS, Khabirov FA, Bolsun DD, Zinkina-Orikhan AV, Linkova YN, Chernovskaya TV.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022 Aug 31; 122(1):62-71. PubMed ID: 35175704
    [Abstract] [Full Text] [Related]

  • 14. Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis.
    Brück W, Zamvil SS.
    Expert Rev Clin Pharmacol; 2012 May 31; 5(3):245-56. PubMed ID: 22697588
    [Abstract] [Full Text] [Related]

  • 15. Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree.
    Cutter GR, Knappertz V, Sasson N, Ladkani D.
    BMC Neurol; 2016 Sep 17; 16():176. PubMed ID: 27639853
    [Abstract] [Full Text] [Related]

  • 16. The effects and side effects of laquinimod for the treatment of multiple sclerosis patients: a systematic review and meta-analysis of clinical trials.
    Rouhi F, Mohammadpour Z, Noureini SK, Abbastabar H, Harirchian MH, Bitarafan S.
    Eur J Clin Pharmacol; 2020 May 17; 76(5):611-622. PubMed ID: 32020320
    [Abstract] [Full Text] [Related]

  • 17. Oral laquinimod therapy in relapsing multiple sclerosis.
    Preiningerova J.
    Expert Opin Investig Drugs; 2009 Jul 17; 18(7):985-9. PubMed ID: 19527103
    [Abstract] [Full Text] [Related]

  • 18. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):387-401. PubMed ID: 20089952
    [Abstract] [Full Text] [Related]

  • 19. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr 04; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.
    Chitnis T, Banwell B, Kappos L, Arnold DL, Gücüyener K, Deiva K, Skripchenko N, Cui LY, Saubadu S, Hu W, Benamor M, Le-Halpere A, Truffinet P, Tardieu M, TERIKIDS Investigators.
    Lancet Neurol; 2021 Dec 04; 20(12):1001-1011. PubMed ID: 34800398
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.